Cigna Group has been granted a patent for a computerized method that determines the efficacy of multiple monitor devices by analyzing health data values from members. The system uses blockchain technology to ensure data security and accuracy, providing personalized health status values for improved device efficacy assessment. GlobalData’s report on Cigna Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cigna Group, Social media analytics was a key innovation area identified from patents. Cigna Group's grant share as of February 2024 was 68%. Grant share is based on the ratio of number of grants to total number of patents.
Automated device efficacy determination for multiple monitor devices
A computerized method for automated device efficacy determination for multiple monitor devices has been granted a patent (Publication Number: US11929163B1). The method involves receiving device and member information, generating keys, and authorizing data streams from the devices. These data streams include health data values sensed by the monitors, which are then transformed into standardized attributes. A personalized micro-engine is used to determine health status values of members based on the data, aggregating them to assess device efficacy against a threshold.
The method further includes features such as determining reimbursement rates for vendors based on device efficacy, displaying outcomes on a digital portal, and restricting access to devices based on efficacy. The physical measurements involved in the process include blood pressure, step count, weight, body mass index, blood glucose, among others. The system also utilizes a blockchain key ledger to store keys and standardized attributes, ensuring secure and efficient processing. The method aims to provide a comprehensive and automated approach to evaluating the effectiveness of multiple monitor devices in improving health status, with potential implications for personalized healthcare and vendor performance assessment.
To know more about GlobalData’s detailed insights on Cigna Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
